ZEISS Medical Technology Grows in France:
Breaks Ground for Facility Expansion in La Rochelle
Jena/Germany, La Rochelle/France | Carl Zeiss Meditec AG
- ZEISS expanding location in the region of Nouvelle-Aquitaine
- Room for further growth in a highly attractive work environment
- Mayor Jean-François Fountaine sees investment as “A positive signal for the entire region”
ZEISS Medical Technology is investing in the French region of Nouvelle-Aquitaine. An official ground-breaking ceremony marked the symbolic start of construction on a new, modern production facility in La Rochelle.
The new building will serve as an expansion to the existing location in La Rochelle and is intended to create room for further growth with office and production areas for the manufacture of ophthalmology consumables.
The expansion to the existing facility will add 13,897 m² of floor space, 2,000 m² of which are offices. The environmentally friendly, energy efficient building will provide manufacturing capacity especially for intraocular lenses designed for the treatment of cataracts. Construction will take into account the ecopolitical challenges facing the region, which is seeking to implement the “La Rochelle territoire zéro carbone” project by 2040.
With this expanded production facility, we want to achieve an even higher delivery rate for our solutions and provide our local team with a highly attractive work environment
The expansion is part of a long-term growth strategy of the ZEISS Group as a whole, which will see expansions in Germany as well as many international locations, with the aim of creating scope for new innovations and a growing workforce.
ZEISS has been doing business in France for over 110 years. It employs 860 workers there at its locations in Paris, Fougères, La Rochelle (Périgny) and Rueil Malmaison.
“A positive signal for the entire region”
Jean-François Fountaine, President of the Communauté de l'Agglomération and Mayor of La Rochelle, said: "This is a very positive signal for the economic dynamics of our region. We are delighted to be able to complete this project with ZEISS. ZEISS is becoming a major employer in our region and we fully support the group in these investments.”
Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 4,823 employees worldwide, the Group generated revenue of €2,089.3m in fiscal year 2022/23 (to 30 September).
The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.
For more information visit our website at www.zeiss.com/med